Fluarix Quadrivalent is prepared from influenza viruses propagated in embryonated chicken eggs. Each of the influenza viruses is produced and purified separately. After harvesting the virus-containing fluids, each influenza virus is concentrated and purified by zonal centrifugation using a linear sucrose density gradient solution containing detergent to disrupt the viruses. Following dilution, the vaccine is further purified by diafiltration.
Each influenza virus solution is inactivated by the consecutive effects of sodium deoxycholate and formaldehyde leading to the production of a “split virus.” Each split inactivated virus is then suspended
Fluarix Quadrivalent is thimerosal-free.
Fluarix Quadrivalent has been standardized according to U.S. Public Health Service (USPHS) requirements for the 2019-2020 influenza season and is formulated to contain 60 micrograms (mcg) hemagglutinin (HA) per 0.5-mL dose, in the recommended ratio of 15 mcg HA of each of the following 4 influenza virus strains (2 A strains and 2 B strains): A/Brisbane/02/2018 (H1N1) pdm09 (IVR-190), A/Kansas/14/2017 (H3N2) NYMC X-327, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Fluarix Quadrivalent is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
Fluarix Quadrivalent is administered as an intramuscular injection.
Fluarix Quadrivalent is approved for use in persons aged 6 months and older
The preferred sites for intramuscular injection are the anterolateral thigh for children aged 6 through 11 months and the deltoid muscle of the upper arm for persons aged 12 months and older if muscle mass is adequate.
- 6 months through 8 years: Not previously vaccinated with influenza vaccine: Two doses (0.5-mL each) at least 4 weeks apart
- 6 months through 8 years: Vaccinated with influenza vaccine in a previous season One or 2 doses (0.5-mL each)
- 9 years and older: One 0.5-mL dose